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Summary
 
In a murine model of respiratory syncytial virus disease, prior sensitization to the attachment
glycoprotein (G) leads to pulmonary eosinophilia and enhanced illness. Three different ap-
proaches were taken to dissect the region of G responsible for enhanced disease and protection
against challenge. First, mutant viruses, containing frameshifts that altered the COOH terminus
of the G protein, were used to challenge mice sensitized by scarification with recombinant vac-
cinia virus (rVV) expressing wild-type G. Second, cDNA expressing these mutated G proteins
were expressed by rVV and used to vaccinate mice before challenge with wild-type respiratory
syncytial virus (RSV). These studies identified residues 193–205 to be responsible for G-induced
weight loss and lung eosinophilia and showed that this region was not was not necessary for in-
duction of protective immunity. Third, mice were sensitized using an rVV that expressed only
amino acids 124–203 of the G protein. Upon RSV challenge, mice sensitized with this rVV
developed enhanced weight loss and eosinophilia. This is the first time that a region within
RSV (amino acids 193–203) has been shown to be responsible for induction of lung eosino-
philia and disease enhancement. Moreover, we now show that it is possible to induce protec-
tive immunity with an altered G protein without inducing a pathological response.
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espiratory syncytial virus (RSV) is the leading cause
of bronchiolitis and viral pneumonia among infants
and young children (1, 2). Primary infection with RSV
usually occurs within the first or second year of life with
children between the ages of 6 wk and 9 mo of age at the
greatest risk of developing serious illness. RSV bronchiolitis
is associated with the development of atopy and asthma in
later years (3). Because bronchiolitis is the leading cause of
hospital admissions for infants in the western world, devel-
opment of a safe and effective vaccine is a high priority.
A cautious approach to RSV vaccine development has
been taken since the failure of vaccine trials in the 1960’s.
In these trials children were inoculated intramuscularly
with formalin-inactivated RSV. After subsequent natural
exposure to RSV, children who had been given the RSV
vaccine had greater morbidity and mortality than control
vaccinees (4–7). Postmortem examination of these children
showed peribronchiolar infiltration and excess eosinophils
in the lungs and blood (4, 7).
In a BALB/c mouse model, this type of enhanced pa-
thology can be reproduced by scarifying mice with recom-
binant vaccinia virus (rVV) expressing only the G protein
of RSV followed by intranasal inoculation of infectious
RSV (8). The G protein is a highly glycosylated membrane
protein thought to be responsible for viral attachment to
the host cell. It is produced in both a secreted and mem-
brane-bound form; the function of the secreted form is un-
known, but it may function as a decoy for neutralizing an-
tibodies. The COOH terminus of the G protein varies
amongst the different strains of RSV, although in human
RSV there is a conserved region (amino acids 164–176)
that is believed to be the receptor attachment site (9).
In the BALB/c mouse model, vaccination with individ-
ual RSV proteins expressed in VVs generates different im-
munological and pathological responses upon intranasal ex-
posure to RSV (2). Vaccination with rVV expressing the
fusion protein (F) of RSV leads to the generation of CTLs
and CD4
 
1
 
 cells with a Th1 type of phenotype (i.e., high
IFN-
 
g
 
 and
 
 
 
no IL-4 or IL-5), whereas rVV expressing the
matrix protein (M2) generates a CTL response with little or
no T helper response. By contrast, vaccination with rVV
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expressing the G protein leads to the generation of a Th2
type of response (less IFN-
 
g
 
 and some IL-4 and IL-5) with
an eosinophilic influx into the alveolar space (8, 10, 11).
This eosinophilic influx and vaccine-enhanced illness re-
sembles the pathology found in the children from the
1960’s vaccine trials.
To aid the development of a safe and effective vaccine,
this murine model of vaccine-enhanced illness has been
used to investigate immunopathological mechanisms in-
volved in RSV illness (2). Since eosinophilia depends on
CD4
 
1
 
 T cell recognition of G (12, 13), we mapped G pro-
tein regions in BALB/c mice using RSV frameshift mu-
tants and rVV expressing partial or mutant G proteins.
These studies identified an 11-amino acid portion of the G
protein that is involved in the generation of pulmonary
eosinophilia and vaccine-enhanced weight loss, but is not
essential for the induction of protective immunity.
 
Materials and Methods
 
Viruses.
 
RSV and rVVs were grown on HEp-2 cells and ti-
tered as previously described (8). Frameshift mutants were iso-
lated by selecting escape variants in vitro with anti-G monoclonal
antibody (63G) (14). All stocks were free of mycoplasma contam-
ination as determined by DNA hybridization (Genprobe Inc.,
San Diego, CA).
 
Construction of rVVs Expressing G Protein Frameshift Mutants.
 
pGEM4 derived plasmids encoding the G proteins of frameshift
mutants R63/1/2/3 and R63/2/4/8 have been described previ-
ously (14). The plasmid encoding the double frameshift G protein
mutant R63/2/4/1 was derived from R63/2/4/8; in this case, an
extra adenosine was inserted after nucleotide 648 by PCR-based
site-directed mutagenesis as described (15). The G protein inserts
of the above plasmids were isolated by digestion with HindIII and
EcoRI, blunt-ended with Klenow polymerase, and ligated to
SmaI linearized pSC11 vector. CV-1 cells were infected with the
WR strain of VV and immediately transfected with the pSC11-
derived plasmids. Progeny virus was plaque purified three times
on HuTK-124B cells in the presence of 15 
 
m
 
g/ml of bromode-
oxyuridine to select for thymidine kinase–negative recombinants.
The rVVG27 (expressing amino acids 124–203) and rVVTer
(empty vector) vaccinia viruses were a gift of Dr. M. Trudel
(Centre de Recherche en Virologie, Institut Armand-Frappier,
Québec, Canada) and have been described previously (16). rVVG
contains the insert for the whole G protein and rVV
 
b
 
gal contains
the LacZ gene inserted into the vaccinia vector as a negative con-
trol in all experiments (17, 18).
 
Mouse Infections.
 
Anesthetized 8–10-wk-old female BALB/c
mice (Harlan Olac, Bicester, UK) were scarified with 2 
 
3 
 
10
 
6
 
PFU recombinant vaccinia at the base of the tail. After 2 wk, mice
were intranasally inoculated with 1.5 
 
3 
 
10
 
6
 
 PFU/mouse of Long
and RSV mutants or 3 
 
3 
 
10
 
6
 
 PFU/mouse of RSV A2 strain.
 
Measurement of Eosinophilia in the Bronchoalveolar Lavage.
 
7 d af-
ter RSV infection, bronchoalveolar lavage (BAL) fluid was col-
lected as previously described (19). In brief, individual mice were
terminally anesthetized with pentobarbitone and bled via the
femoral artery. Lungs were perfused six times with 1 ml of lig-
nocaine in Eagle’s media (Sigma Chemical Co., Poole, UK). 200
 
m
 
l of BAL fluid was cytocentrifuged onto glass slides and stained
with Giemsa’s reagent for cytological analysis. Eosinophils were
counted by flow cytometry as the proportion of the granulocytes
compared with total cells and confirmed with microscopic exam-
ination of cytospin slides to distinguish between polymorphonu-
clear cells and eosinophils.
 
Titration of RSV from Mouse Lungs.
 
Mice were scarified with
recombinant vaccinias 14 d before challenge with whole RSV. 4 d
after challenge with RSV, whole lungs were disrupted using glass
homogenizers (Jencons, Leighton Buzzard, UK) in 1.3 ml RPMI
(Sigma Chemical Co.) supplemented with 2 mM glutamine
(GIBCO BRL, Paisley, Scotland), 100 U/ml penicillin, and 100
 
m
 
g/ml streptomycin on ice. Homogenates were clarified at
10,000 
 
g
 
 for 1 min. 50 
 
m
 
l of supernatant and twofold serial dilu-
tions thereof were titrated on HEp-2 monolayers in 96-well
plates and plaques were assayed as previously described (8). The
theoretical limit of detection for this assay was 5 PFU/lung.
 
Statistical Analysis.
 
Kruskal-Wallis tests were used to test for
effects between groups and Mann-Whitney U tests were used to
perform comparisons between the experimental and control groups.
Data analysis was performed using SPSS statistical software.
 
Results
 
Mapping of the Eosinophilic Induction Using RSV Mutants.
 
A series of RSV escape mutants were generated using a
monoclonal antibody against the G protein (14). These
mutants contain frameshift mutations generating G proteins
with truncations and/or alterations in the COOH terminus
of the protein (Fig. 1). Mice were scarified with rVVG or
rVV
 
b
 
gal (control construct) and 2 wk were later intrana-
sally challenged with the parental Long strain or one of the
different mutant viruses. 7 d after infection, BAL fluid was
collected and the percentage of eosinophils in the BAL was
assessed. As in primary infection, mice scarified with rVV
 
b
 
gal
and challenged with either Long or mutant viruses showed
no eosinophilia. However, mice scarified with rVVG and
challenged with whole RSV showed marked pulmonary
eosinophilia except for one mutant. Mutant 63/1/2/3
failed to induce eosinophilia. Mice scarified with rVVG and
challenged with mutant 63/1/2/3 generated a low level of
eosinophilia similar to mice scarified with rVV
 
b
 
gal (
 
P
 
$
 
0.86) (Fig. 2). The low level of eosinophilia observed in
mice scarified with rVVG after intranasal challenge with
63/1/2/3 was significantly different from mice scarified
with rVVG followed by either Long, 63/2/4/1, or 63/2/
4/8 (
 
P
 
 
 
#
 
0.01, 0.01, and 0.01, respectively). The differ-
ences between mutant 63/1/2/3 and 63/2/4/8 lie between
amino acids 193 and 205 (Fig. 1). From these data, the por-
tion of the G protein responsible for eosinophil induction
can be localized to this region.
A possible explanation for this finding is that the large
deletion in 63/1/2/3 altered viral infectivity and subse-
quent eosinophilia generation. Viral lung titers on days 4
and 7 after infection showed no differences between the
parental Long strain virus and viral mutants (data not
shown). Despite the large alteration of the COOH termi-
nus of the G protein, all mutant viruses infected the lungs
efficiently and replicated as well as Long strain virus and all
were cleared by day 7.
 
Mapping of the Eosinophilic Antigen Using rVVs.
 
To com-
plement the studies described above and ensure that the 
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eosinophilia was due only to sensitization to the attachment
protein G, rVVs expressing mutant G proteins were used to
sensitize mice. Mice were scarified with recombinant vac-
cinia and challenged intranasally with wild-type RSV (A2
strain) after 14 d. The G protein of the A2 strain is 95% ho-
mologous to Long strain and is identical within region 193–
205. Mirroring the first set of studies, no eosinophilia was
observed in the BAL of mice scarified with rVV63/1/2/3
(Fig. 3 
 
A
 
). The level of eosinophilia in rVV63/1/2/3-vac-
cinated mice was not significantly different from rVV
 
b
 
gal-
primed mice (
 
P
 
 $
 
0.556) and was significantly reduced com-
pared with that seen in mice primed with rVVG, rVV63/
2/4/1, or rVV63/2/4/8 (
 
P
 
 
 
#
 
0.02, 0.02, and 0.05, respec-
tively). To confirm that the lack of eosinophilia observed in
mutant rVV63/1/2/3 mice was not due to a loss of stability
or secondary structures, mice were scarified with recombi-
nant vaccinia (rVVG27) expressing 80 amino acids of the G
protein (124–203) (Fig. 1). After intranasal RSV challenge,
marked eosinophilia was observed, similar to that of mice
primed with rVVG (
 
P 
 
$
 
0.29) and significantly greater than
in control mice primed with rVVTer (the control con-
struct) (
 
P 
 
#
 
0.03) (Fig. 3 
 
B
 
). This confirms that the eosino-
philic region lies within this 80-amino acid portion of the
G protein. Together, these data using mutant viruses and
rVV with inserted mutant G proteins or portions of the G
protein, suggest that amino acids 193–203 contain the crit-
ical region responsible for lung eosinophilia.
 
Deletion of the Portion of G Protein Responsible for G-enhanced
Weight Loss.
 
The level of eosinophilia in the lungs is only
one measure of vaccine-enhanced illness; another is weight
loss. Each mouse was weighed daily after intranasal challenge
with RSV. Sensitization with the G protein from mutant
virus 63/1/2/3 did not significantly enhance weight loss
during RSV challenge compared with control vaccination
with rVV
 
b
 
gal, whereas rVVG or any of the other mutants
did enhance weight loss (Fig. 4 
 
A
 
). To confirm that this re-
gion contains an epitope that is responsible for vaccine-
enhanced weight loss, recombinant vaccinia expressing
amino acids 124–203 of the G protein (rVVG27) was used
to prime mice followed by intranasal challenge with live
RSV (Fig. 4 
 
B
 
). Mice sensitized with this portion of the G
protein suffered marked weight loss equal to that caused by
wild-type G. These data illustrate that the portion of the G
protein responsible for pulmonary eosinophilia is also re-
sponsible for vaccine-enhanced weight loss.
 
Protection against RSV Challenge.
 
To examine whether
rVV63/1/2/3 could still provide protection even though it
does not induce eosinophilia, mice were scarified with re-
combinant vaccinias and challenged intranasally with wild-
type RSV. All mice vaccinated with either of the frameshift
mutants (rVV63/2/4/8 or rVV63/1/2/3) or with wild-
type G (rVVG) were protected from RSV infection at day
4 (Fig. 5) and no virus was recovered from the lungs of any
mice at day 7 (data not shown). These results confirm that
it is possible to protect mice from subsequent RSV infec-
tion without inducing lung eosinophilia.
 
Discussion
 
This is the first study to show that a single region within
the G protein is responsible for enhanced illness and lung
eosinophilia and that in its absence it is possible to induce
protective immunity without pathology. The critical im-
portance of this region for lung eosinophilia was evident
both at the priming (rVV63/1/2/3) and challenge (63/1/
Figure 2. Eosinophilic influx in the BAL fluid following scarification
with rVVbgal (filled bars) or rVVG (checked bars) after intranasal inocula-
tion with mutant RSV. Data shown is representative of four experiments
and each bar represents the mean percentage of individual eosinophil
counts in each group 6 SEM (n 5 4). Significant differences (P #0.05) be-
tween rVVG and rVVbgal using Mann-Whitney paired comparisons test
are indicated by **. The significance levels between rVVG and rVVbgal
vaccinated mice are as follows: Long, P #0.03; 63/2/4/1, P #0.03; 63/
2/4/8, P #0.03; 63/1/2/3, P #0.86.
Figure 1. The primary struc-
ture of the G protein from RSV
(Long strain) and the mutants
used in this study (14). The stip-
pled region indicates the trans-
membrane domain and hashed
boxes denote amino acids changed
due to frameshift mutations. The
location of the intracellular (IC),
transmembrane (TM), mucinoid
I, mucinoid II, and conserved
domains are indicated. 
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2/3) phases of the immune response. Mapping eosinophilia
induction with the mutant G proteins and rVVG27 locates
the critical region to be amino acids 193–203. There are
two possible explanations for this finding. First, the muta-
tion in 63/1/2/3 could have eliminated all CD4
 
1
 
 T cell
recognition of the G protein. Since G-induced RSV dis-
ease is mainly a T cell–mediated, immunopathological pro-
cess, a reduction in the CD4
 
1
 
 T cell response would lead
to less cellular infiltration into the lungs, less eosinophilia,
no RSV-specific antibody response, and less weight loss. A
second possibility is that the mutation introduced into 63/
1/2/3 does not eliminate the entire CD4
 
1
 
 response but
rather a vigorous, eosinophil-inducing component thereof.
We believe this to be the case since priming with rVV63/
1/2/3 generates an appreciable antibody response and a
pulmonary lymphocytic infiltrate similar to that seen in
wild-type G-sensitized mice, but with a significant decrease
in the ratio of CD4
 
1
 
:CD8
 
1
 
 cells (data not shown). This
suggests that a strong CD4
 
1
 
 T cell response is abolished by
the alteration of residues 193–203 and that this response is
essential for induction of lung eosinophilia. Recently, using
overlapping peptides, a T cell epitope that induces a Th2
response has been mapped to amino acids 184–198 (19a).
This peptide includes six residues from the critical region
mapped in our study (KPGKKT). Using a predictive algo-
rithm for class II MHC binding peptides (strong and weak
anchor positions: 1, 4, 9: I, K or R, K, respectively) (20),
we have identified two possible I-E
 
d
 
 epitopes, both of
which would be disrupted in the 63/1/2/3 mutant. These
potential epitopes are located at amino acids 185-193
(
 
I
 
CK
 
R
 
IPNK
 
K
 
) and 189–197 (
 
I
 
PN
 
K
 
KPGK
 
K
 
) (bold type
indicates anchor and subanchor residues).
In other viral systems, single epitopes have been shown
to be responsible for Th2-like CD4
 
1
 
 responses. Proteins
from mouse hepatitis virus (JHM; reference 21), hepatitis B
virus (22), and retroviruses (23) have been shown to gener-
ate Th2 responses and have been mapped using peptides
and T cell clones and lines. Unlike our study, in none of
these systems has it been possible to examine the effects of
altering these epitopes upon the host immune response and
induction of pathology. Interestingly, the critical epitope in
JHM virus is also I-E
 
d
 
–restricted (ILNKPRQKR
 
) 
 
and con-
tains at least four identical or similar residues to the proposed
critical motifs of RSV G. It is possible that these homolo-
gous epitopes have similar binding affinities for MHC class
II molecules, thus skewing towards a Th2-type response (24).
In this and in previous studies, induction of eosinophilia
is indicative of a Th2-type response (10, 11, 25). The re-
cruitment of eosinophils into the alveolar space could be
due to IL-5 production (26) or the induction of chemo-
kines such as eotaxin (27) or RANTES (regulated on acti-
vation, T cell expressed and secreted; reference 28). In our
study, this same region is also responsible for the increased
weight loss that is observed upon challenge. Weight loss,
however, is not a specific indicator of Th2-type, eosino-
philic pathology since mice lose weight late in a primary
Figure 3. Eosinophilia in the
BAL of mice primed with rVVs
expressing mutant G proteins (A)
or portions of the G protein (B)
followed by intranasal inocula-
tion with A2 RSV. 2 wk after
scarification with rVVbgal,
rVVG, rVV63/1/2/3, rVV63/2/
4/1, or rVV63/2/4/8 (A), or
rVVTer or rVVG27 (B), mice
were challenged intranasally with
wild-type RSV (strain A2). Rep-
resentative data of 3 experiments
are shown where circles represent
single mice and open squares rep-
resent the mean percentage of
eosinophils in the BAL fluid
from each group 6 SEM. Signif-
icant differences between the
mean eosinophilia-generated rV-
Vbgal are indicated by **.
Figure 4. Weight loss after
vaccination with rVVG mu-
tants. Weights were taken daily
after intranasal challenge with
wild-type A2. Data are expressed
as a mean percentage (3–4 per
group) of the original weight
(day 5 0) 1 SEM. Representa-
tive experiment from three ex-
periments.1925 Sparer et al. Brief Definitive Report
infection and may show disease enhancement due to sensi-
tization to other RSV proteins (10). Hussell et al. have
shown that IL-12 treatment of mice primed with rVVG in-
duces a Th1-type response and diminishes eosinophilia but
weight loss is unaffected or in some cases enhanced (29).
Our data indicate that region 193–203 of the G protein not
only induces eosinophilia (probably via the Th2 pathway),
but also induces an immune response (such as TNF-a; ref-
erence 30) that is responsible for increased weight loss.
These findings provide a framework which may allow the
development of an RSV vaccine without vaccine-enhanced
illness. In the mouse model of RSV, vaccine-enhanced ill-
ness presents two possible pathways for eosinophil induc-
tion: first, a CD41 response to eosinophilic epitopes within
the primary structure of the G protein such as described
here, or second, the elimination of the CD81 response that
controls the Th2 response (31). We have recently shown
that it is possible to generate eosinophilia to the F protein
of RSV when CD81 cells are deleted. Normally, priming
with the F protein of RSV generates a Th1-type response
and virus-specific CTLs that are an abundant source of
IFN-g. When CD81 T cells are deleted, the response is
switched to a Th2-type response that generates lung eosi-
nophilia. It appears that in the F response, CD81 cells are
responsible for controlling the Th2-type response, most
likely through the production of IFN-g (13). Similarly, the
failure of the formalin-inactivated RSV vaccine trials could
have been due to the lack of CD81 T cell induction since
soluble antigen is processed and presented via the MHC class
II pathway. Both aspects of the immune response need to
be considered for the development of future RSV vaccines.
Our results suggest that it is possible to induce a protec-
tive immune response with the G protein without inducing
a detrimental eosinophilic response. Since the G protein
does not induce a CTL response in BALB/c mice (32),
eosinophil induction could in part be due to the lack of a
CD81 response. In spite of this, we have shown that it is
possible to induce protective immunity with the G protein
if the eosinophilogenic portion has been altered. Vaccines
need to induce a CD41 response to promote B cell pro-
duction of protective antibody, but IFN-g production by
CD81 cells may also be essential to protect against augmen-
tation of illness. However, induction of a strong and unop-
posed CD41 response can also be detrimental. Sensitization
with the M2 protein alone leads to enhanced illness, and
transfer of isolated CD41 T cells causes augmented disease
as well (10, 33). An ideal vaccine should strike a balance
between inducing CD41 and CD81 T cell responses. Vac-
cination that stimulates either a CD41 or CD81 T cell re-
sponse alone might lead to pathological consequences (34).
Whether these tenets for vaccine development will hold
true in an outbred human population remains to be tested.
Figure 5. RSV titers from the lungs of mice vaccinated with rVVs.
Mice were scarified with rVVs expressing either bgal, wild-type G, or
mutated G proteins (rVV63/2/4/8 or rVV63/1/2/3) and challenged in-
tranasally with whole RSV. 4 d after challenge, lungs were homogenized
and assayed for RSV. Titers from individual mice are shown from one of
two separate experiments which gave similar results.
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